+

WO2002005785A1 - Aerosols therapeutiques a liberation modulee - Google Patents

Aerosols therapeutiques a liberation modulee Download PDF

Info

Publication number
WO2002005785A1
WO2002005785A1 PCT/US2001/041129 US0141129W WO0205785A1 WO 2002005785 A1 WO2002005785 A1 WO 2002005785A1 US 0141129 W US0141129 W US 0141129W WO 0205785 A1 WO0205785 A1 WO 0205785A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
medicament
mixture
foregoing
group
Prior art date
Application number
PCT/US2001/041129
Other languages
English (en)
Inventor
Akwete L. Adjei
Yaping Zhu
Anthony J. Cutie
Original Assignee
Aeropharm Technology Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeropharm Technology Incorporated filed Critical Aeropharm Technology Incorporated
Priority to AU2001281288A priority Critical patent/AU2001281288A1/en
Publication of WO2002005785A1 publication Critical patent/WO2002005785A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Definitions

  • This invention relates to a modulated release aerosol formulation, and more particularly, to a medicinal aerosol formulation comprising polymeric vesicles which entrap a selected medicament and provide slow release thereof.
  • Drugs currently administered by inhalation come primarily as liquid aerosol formulations. For biotherapeutic drugs, this may present a problem, as many of these medicaments are unstable in aqueous environments for extended periods of time. Many drug and excipient systems contain biodegradable carriers, such as poly(lactide-co-glycolides) which have been developed for biotherapeutic proteins and peptides [Liu, R., et al, Biotechnol. Bioeng., 37:177-184 (1991)]. These medicaments, presumably, are adequately protected in their carrier systems, and thus do not undergo as much denaturation as realized in aqueous media.
  • the clinical and pharmaceutical chemistry sciences in an attempt to accomplish the highest level of therapeutic benefit for these compounds, have resorted to chemical modifications as a principal mode for improving biological activity of these drugs in the body of the patient.
  • the mode of drug administration to the body has also gradually expanded from oral and parenteral to transdermal, rectal and the pulmonary routes of administration, i.e., nose and lung.
  • Success and achievement with these drug delivery approaches are mixed largely due to lack of acceptance of the newer, complex molecules that must be used for treating difficult diseases of the body, e.g., infections, malignancies, cardiovascular, endocrine, neurologic diseases, and a variety of immunologically compromised diseases, like AIDS.
  • a fluid propelled formulation system comprising an active pharmaceutical ingredient (“API") that is stable, easily manufactured, and therapeutically effective when administered as fluid dispersed particles to the lung of a patient, e.g. a human being or another animal, as inhalation aerosols are widely accepted in clinical therapeutics worldwide.
  • API active pharmaceutical ingredient
  • This invention relates to a modulated release aerosol formulation, and more particularly, to a therapeutic formulation comprising a selected medicament associated with a polymeric matrix.
  • This invention involves a stable, modulated release aerosol formulation suitable for pressurized delivery, which comprises (1) a macromolecular medicament or drug, (2) a polymeric construct into which the drug is associated, i.e. encapsulated therewithin, or being a part of the construct, (3) a suitable propellant, and (4) a suitable stabilizer.
  • the polymeric construct comprising a block copolymer, provides a modulated release of the associated, i.e. encapsulated, drug to the body of a patient, e.g. a human being or another animal, when the formulation is administered to the patient's respiratory tract.
  • a suitable macromolecular medicament or drug is one which is suitable for administration by inhalation, the inhalation being used for oral and nasal inhalation therapy.
  • a stable, colloidal dispersion of a medicament in a fluid e.g. air, hydrocarbon gases, chlorofluorocarbon (CFC) propellants or non-CFC propellants, such as tetrafluoroethane (HFA-134a) and heptafluoropropane (HFA-227), is described.
  • a fluid e.g. air, hydrocarbon gases, chlorofluorocarbon (CFC) propellants or non-CFC propellants, such as tetrafluoroethane (HFA-134a) and heptafluoropropane (HFA-227)
  • a stabilizer of a polyionic species such as an amino acid and a small molecule peptide, as an inactive formulation component, which triggers loss of adhesive bond strength between the medicament particles, may optionally be employed.
  • An electret or sterially stabilized aerocoUoid particles of the selected medicaments is thus formed.
  • An electret is the electrostatic equivalent of a permanent magnet but can be susceptible to breakdown in the presence of moisture, such as that present in air or at ambient humidity conditions of the respiratory tract. Accordingly, the present invention applies to dry powder aerosols, portable nebulizer systems, as well as pressurized metered dose inhaler formulation systems.
  • the resultant aerocoUoid is chemically and physically stable and can remain in suspension until the selected medicament or drug particles reach the alveolar or other absorption sites in the airways of a patient, e.g. human, other animal, being treated.
  • the drug particles should be efficiently trapped at the deposition site as a result of moisture in the ambient, dissolve at a controlled rate in the epithelial lining fluids, and be absorbed at a predictable rate across the biomembranes of the patient, thereby limiting possible deactivation by metabolizing enzymes in the airways.
  • biodegradable means that the block copolymer can chemically break down or degrade within the body to form nontoxic components.
  • the rate of degradation can be the same or different from the rate of drug release.
  • the term "rate of release” from the biodegradable medicament carrier is defined as the amount of medicament released per unit time either to the lung environment or from the lung environment to the systemic circulation of the body of the patient treated.
  • poly(lactide-co-glycolide) shall mean a copolymer derived from the condensation copolymerization of lactic acid and glycolic acid, or, by the ring opening polymerization of . alpha. -hydroxy acid precursors, such as lactide or glycolide.
  • lactide and lactate and "glycolide” and “glycolate” are used interchangeably.
  • peptide shall be used interchangeably when referring to peptide or protein drugs and shall not be limited as to any particular molecular weight, peptide sequence or length, field of bioactivity or therapeutic use unless specifically stated.
  • a suitable medicament to which the subject invention is directed includes a peptide, polypeptide, or protein biotherapeutic medicament ranging from 0.5 K Dalton to 150 K Dalton in molecular size.
  • the peptide, polypeptide, or protein biotherapeutic medicament includes diabetic aids; such as insulins and insulin analogs; amylin; glucagon;.
  • surfactants such as cytokines, chemokines, lymphokines; interleukins, such as taxol, interleukin-1, interleukin-2, and interferons; erythropoetins; thrombolytics and heparins; anti-proteases, antitrypsins and amiloride; rhDNase; antibiotics and other antiinfectives; hormones; and growth factors, such as parathyroid hormones, LH-RH and GnRH analogs; nucleic acids; DDAVP; calcitonins; cyclosporine; ribavirin; enzymes; heparins; hematopoietic factors; cyclosporins; vaccines; immunoglobulins; vasoactive peptides; antisense agents; genes, oligonucleotide, and nucleotide analogs.
  • immunomodulating peptides such as cytokines, chemokines, lymphokines; interle
  • diabetic aid includes natural, synthetic, semi-synthetic and recombinant medicaments such as activin, glucagon, insulin, somatostatin, proinsulin, amylin, and the like.
  • insulin shall be interpreted to encompass insulin analogs, natural extracted human insulin, recombinantly produced human insulin, insulin extracted from bovine and/or porcine sources, recombinantly produced porcine and bovine insulin and mixtures of any of these insulin products.
  • the term is intended to encompass the polypeptide normally used in the treatment of diabetics in a substantially purified form but encompasses the use of the term in its commercially available pharmaceutical form, which includes additional excipients.
  • the insulin is preferably recombinantly produced and may be dehydrated (completely dried) or in solution.
  • insulin analog refers to any form of "insulin” as defined above, wherein one or more of the amino acids within the polypeptide chain has been replaced with an alternative amino acid and/or wherein one or more of the amino acids has been deleted or wherein one or more additional amino acids has been added to the polypeptide chain or amino acid sequences, which act as insulin in decreasing blood glucose levels.
  • insulin analogs include "insulin lispro analogs,” as disclosed in U.S. Pat. No.
  • insulin analogs including LysPro insulin and humalog insulin, and other "super insulin analogs", wherein the ability of the insulin analog to affect serum glucose levels is substantially enhanced as compared with conventional insulin as well as hepatoselective insulin analogs which are more active in the liver than in adipose tissue.
  • Preferred analogs are monomeric insulin analogs, which are insulin-like compounds used for the same general purpose as insulin, such as insulin lispro, i.e., compounds which are administered to reduce blood glucose levels.
  • amylin includes natural human amylin, bovine, porcine, rat, rabbit amylin, as well as synthetic, semi-synthetic or recombinant amylin or amylin analogs including pramlintide and other amylin agonists, as disclosed in U.S. Pat. No. 5,686,411 and U.S. Pat. No. 5,854,215, both of which are incorporated hereinto by reference in their entirety.
  • immunomodulating proteins include cytokines, chemokines, lymphokines complement components, immune system accessory and adhesion molecules and their receptors of human or non-human animal specificity.
  • Useful examples include GM-CSF, IL-2, TJ -12, OX40, OX40L (gp34), lymphotactin, CD40, CD40L.
  • Useful examples include interleukins, for example interleukins 1 to 15; interferons alpha, beta or gamma; tumour necrosis factor, granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), granulocyte colony stimulating factor (G-CSF), chemokines, such as neutrophil activating protein (NAP); macrophage chemoattractant and activating factor (MCAF), RANTES, macrophage inflammatory peptides MLP-la and MEP-lb, complement components and their receptors, or an accessory molecule, such as B7.1, B7.2, ICAM-1, 2 or 3 and cytokine receptors.
  • interleukins for example interleukins 1 to 15; interferons alpha, beta or gamm
  • Immunomodulatory proteins can for various purposes be of human or non-human animal specificity and can be represented, for present purposes, as the case may be and as may be convenient, by extracellular domains and other fragments with the binding activity of the naturally occurring proteins, and muteins thereof, and their fusion proteins with other polypeptide sequences, e.g. with immunoglobulin heavy chain constant domains.
  • nucleotide sequences encoding more than one immunomodulating protein are inserted, they can, for example, comprise more than one cytokine or a combination of cytokines and accessory/adhesion molecules.
  • Interferon or "TEN” as used herein means the family of highly homologous species-specific proteins that inhibit viral replication and cellular proliferation and modulate immune response. Interferons are grouped into three classes based on their cellular origin and antigenicity, namely, alpha-interferon (leukocytes), beta-interferon (fibroblasts) and gamma-interferon (immunocompetent cells). Recombinant forms and analogs of each group have been developed and are commercially available. Subtypes in each group are based on antigenic/structural characteristics. At least 24 interferon alphas (grouped into subtypes A through H) having distinct amino acid sequences have been identified by isolating and sequencing DNA encoding these peptides.
  • alpha.-interferon alpha interferon
  • interferon alpha human leukocyte interferon
  • Purified natural human alpha inteferons and mixtures thereof which may be used in the practice of the invention include but are not limited to Sumiferon RTM interferon alpha-nl available from Sumitomo, Japan; Welfferong interferon alpha-nl (Ins) available from Glaxo-Wellcome Ltd., London, Great Britain; and Alferon RTM interferon alpha-n3 available from the Purdue Frederick Co., Norwalk, Conn.
  • erythropoietin applies to synthetic, semi-synthetic, recombinant, natural, human, monkey, or other animal or microbiological isolated polypeptide products having part or all of the primary structural conformation (i.e., continuous sequence of amino acid residues) and one or more of the biological properties (e.g., immunological properties and in vivo and in vitro biological activity) of naturally-occurring erythropoietin, including allelic variants thereof.
  • polypeptides are also uniquely characterized by being the product of procaryotic or eucaryotic host expression (e.g., by bacterial, yeast and mammalian cells in culture) of exogenous DNA sequences obtained by genomic or cDNA cloning or by gene synthesis.
  • procaryotic or eucaryotic host expression e.g., by bacterial, yeast and mammalian cells in culture
  • Products of microbial expression in vertebrate (e.g., mammalian and avian) cells may be further characterized by freedom from association with human proteins or other contaminants which may be associated with erythropoietin in its natural mammalian cellular environment or in extracellular fluids such as plasma or urine.
  • yeast e.g., Saccaromyces cerevisiae
  • procaryote e.g., E.
  • polypeptides of the invention are glycosylated with mammalian or other eucaryotic carbohydrates or may be nonglycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue (at position -1).
  • Novel glycoprotein products of the invention include those having a primary structural conformation sufficiently duplicative of that of a naturally-occurring (e.g., human) erythropoietin to allow possession of one or more of the biological properties thereof and having an average carbohydrate composition which differs from that of naturally-occurring (e.g., human) erythropoietin.
  • heparins and “thrombolytics” include anti-clotting factors such as heparin, low molecular weight heparin, tissue plasminogen activator (TPA), urokinase (Abbokinase) and other factors used to control clots.
  • TPA tissue plasminogen activator
  • Abbokinase urokinase
  • anti-proteases and “protease-inhibitors” are used interchangeably and apply to synthetic, semi-synthetic, recombinant, naturally- occurring or non-naturally occurring, soluble or immobilized agents reactive with receptors, or act as antibodies, enzymes or nucleic acids. These include receptors which modulate a humoral immune response, receptors which modulate a cellular immune response (e.g., T-cell receptors) and receptors which modulate a neurological response (e.g., glutamate receptor, glycine receptor, gamma-amino butyric acid (GABA) receptor).
  • GABA gamma-amino butyric acid
  • cytokine receptors include the cytokine receptors (implicated in arthritis, septic shock, transplant rejection, autoimmune disease and inflammatory diseases), the major histocompatibility (MHC) Class I and II receptors associated with presenting antigen to cytotoxic T-cell receptors and or T-helper cell receptors (implicated in autoimmune diseases) and the thrombin receptor (implicated in coagulation, cardiovascular disease).
  • MHC major histocompatibility
  • cytotoxic T-cell receptors and or T-helper cell receptors include cytotoxic T-cell receptors and or T-helper cell receptors
  • thrombin receptor included in coagulation, cardiovascular disease.
  • antibodies which recognize self -antigens such as those antibodies implicated in autoimmune disorders and antibodies which recognize viral (e.g., HJN, herpes simplex virus) and/or microbial antigens.
  • hormones and “growth factors” include hormone releasing hormones such as growth hormone, thyroid hormone, thyroid releasing hormone (TRH), gonadotropin-releasing hormone (GnRH), leuteininzing hormone, leuteininzing hormone-releasing hormone (LHRH, including the superagonists and antagonists, such as leuprolide, deltirelix, gosorelin, nafarelin, danazol, etc.) sourced from natural, human, porcine, bovine, ovine, synthetic, semi-synthetic, or recombinant sources. These also include somatostatin analogs such as octreotide (Sandostatin).
  • biotherapeutics include medicaments for uterine contraction (e.g., oxytocin), diuresis (e.g., vasopressin), neutropenia (e.g., GCSF), medicaments for respiratory disorders (e.g., superoxide dismutase), RDS (e.g., surfactants, optionally including apoproteins), and the like.
  • oxytocin e.g., oxytocin
  • diuresis e.g., vasopressin
  • neutropenia e.g., GCSF
  • medicaments for respiratory disorders e.g., superoxide dismutase
  • RDS e.g., surfactants, optionally including apoproteins
  • enzymes include recombinant deoxyribonuclease such as D ⁇ Ase (Genentech), proteases (e.g., serine proteases such as trypsin and thrombin), polymerases (e.g., RNA polymerases, DNA polymerases), reverse transcriptases and kinases, enzymes implicated in arthritis, osteoporosis, inflammatory diseases, diabetes, allergies, organ transplant rejection, oncogene activation (e.g., dihydrofolate reductase), signal transduction, self -cycle regulation, transcription, DNA replication and repair.
  • D ⁇ Ase Genetech
  • proteases e.g., serine proteases such as trypsin and thrombin
  • polymerases e.g., RNA polymerases, DNA polymerases
  • reverse transcriptases and kinases enzymes implicated in arthritis, osteoporosis, inflammatory diseases, diabetes, allergies, organ transplant rejection, oncogene activ
  • nucleic acids includes any segment of DNA or RNA containing natural or non-naturally occurring nucleosides, or other proteinoid agents capable of specifically binding to other nucleic acids or oligonucleotides via complementary hydrogen-bonding and also are capable of binding to non-nucleic acid ligates.
  • Bock, L., et al. Nature 355:564-566 (1992) which reports inhibition of the thrombin-catalyzed conversion of fibrinogen to fibrin using aptamer DNA.
  • biological molecules for which lead molecules can be synthesized and selected and combined in accordance with the invention include, but are not limited to, agonists and antagonists for cell receptors, neurotransmitters, toxins and venoms, viral epitopes, hormones, opiates, steroids, peptides, enzyme substrates and inhibitors, cofactors, drugs, lectins, sugars, oligonucleotides, nucleic acids, oligosaccharides, lipids, proteins, and analogs of any of the foregoing molecules.
  • analog refers to a molecule, which shares a common functional activity with the molecule to which it is deemed to be comparable and typically shares common structural features as well.
  • recombinant refers to any type of cloned biotherapeutic expressed in procaryotic cells or a genetically engineered molecule, or combinatorial library of molecules which may be further processed into another state to form a second combinatorial library, especially molecules that contain protecting groups which enhance the physicochemical, pharmacological, and clinical safety of the biotherapeutic agent.
  • the term “vaccines” refers to therapeutic compositions for stimulating humoral and cellular immune responses, either isolated, or through an antigen presenting cell, such as an activated dendritic cell, that is able to activate T- cells to produce a multivalent cellular immune response against a selected antigen.
  • the potent antigen presenting cell is stimulated by exposing the cell in vitro to a polypeptide complex.
  • the polypeptide complex may comprise a dendritic cell- binding protein and a polypeptide antigen, but preferably, the polypeptide antigen is either a tissue-specific tumor antigen or an oncogene gene product.
  • antigens such as viral antigens can be used in such combination to produce immunostimulatory responses.
  • the dendritic cell-binding protein that forms part of the immunostimulatory polypeptide complex is GM-CSF.
  • the polypeptide antigen that forms part of the complex is the tumor- specific antigen prostatic acid phosphatase.
  • the polypeptide antigen may be any one of the oncogene product peptide antigens.
  • the polypeptide complex may also contain, between the dendritic cell-binding protein and the polypeptide antigen, a linker peptide.
  • the polypeptide complex may comprise a dendritic cell-binding protein covalently linked to a polypeptide antigen, such polypeptide complex being preferably formed from a dendritic cell binding protein, preferably GM-CSF, and a polypeptide antigen.
  • the polypeptide antigen is preferably a tissue-specific tumor antigen such as prostatic acid phosphatase (PAP), or an oncogene product, such as Her2, p21RAS, and p53; however, other embodiments, such as viral antigens, are also within the scope of the invention.
  • PAP prostatic acid phosphatase
  • an oncogene product such as Her2, p21RAS, and p53
  • immunoglobulins encompasses polypeptide oligonucleotides involved in host defense mechanisms, such as coding and encoding by one or more gene vectors, conjugating various binding moieties of nucleic acids in host defense cells, or coupling expressed vectors to aid in the treatment of a human or animal subject.
  • the medicaments included in this class of polypeptides include IgG, IgE, IgM, IgD, either individually or in a combination with one another.
  • the biotherapeutic medicament is associated with the ABA block copolymer to which it is destined to be combined.
  • association is meant that the medicament is present as a matrix or part of a polymeric construct along with the copolymer or is encapsulated as a microsphere in a biodegradable polymer particle or in a biodegradable polymeric construct particle, or is on a sur ace of such particle, whereby a therapeutically effective amount or fraction (e.g., 95% percent or more) of the biotherapeutic is particulate.
  • the construct particles have a diameter of less than about 10 microns, and preferably less than about 5 microns, in order that the particles can be inhaled into the respiratory tract and/or lungs of the patient being treated, e.g. a human or other animal.
  • a suitable polymeric construct is selected.
  • Such a construct is one which will incorporate therein or encapsulate the selected medicament, e.g. insulin, amylin, octeotride, erythropoietin, immunoglubulin, leuprolide, glucagon, and provide a controlled or modulated release of the medicament therefrom to the sites of action or application of the patient's body, e.g. from the lung to the local surrounding environment of the human being or other animal.
  • the selected medicament e.g. insulin, amylin, octeotride, erythropoietin, immunoglubulin, leuprolide, glucagon
  • a suitable polymer is a biodegradable ABA type block copolymer having an average molecular weight of between about 1500 to about 150,000.
  • These polymers of, example, lactic and glycolic acid derrivatives include the biodegradable, hydrophobic A-block segments selected from a poly(alpha-hydroxy acid), such as a poly(D,L-lactide-coglycolide), a poly(L-lactide-co-glycolide) polybinyl pyrrolidone, etc.
  • a hydrophilic B polymer block selected from the group comprising polyethylene glycol("PEG"), polyethyelene oxide (“PEO”), polyoxyethylene (“PE”),Propylene glycol (PG), etc., having an average molecular weight of between about 1500 and 4000.
  • PEG polyethylene glycol
  • PEO polyethyelene oxide
  • PE polyoxyethylene
  • PG Propylene glycol
  • Such a polymer system forms a construct or a matrix when formed in situ with the selected medicament or medicaments whereby such medicament or medicaments forms part of the construct matrix or is encapsulated within the matrix.
  • the medicament e.g. entrapped insulin
  • the site of action in the body e.g. the lungs, the respiratory tract, node, ear, etc., to the surrounding environment or tissues of the body of the patient treated.
  • the biotherapeutic medicament is present in the inventive formulations in a therapeutically effective amount, that is, an amount such that the biotherapeutic medicament can be administered as a dispersion, aerosol, via oral or nasal inhalation, and cause its desired therapeutic effect, typically preferred with one dose, or through several doses.
  • the drug is typically administered as an aerosol from a conventional valve, e.g., a metered dose valve, through an aerosol adapter also known as an actuator.
  • the term "dosing period” shall be interpreted to mean the period during which administration of the selected medicament may be given to a patient in need thereof by the intrapulmonary route of administration which period may encompass preferably one or more hours in a day or a few days to several weeks but less preferably over a month or under 1 hour, but during which period multiple inhalations are made by the patient and multiple doses of the selected medicament are released and inhaled.
  • amount refers to a quantity or to a concentration as appropriate to the context. The amount of a drug that constitutes a therapeutically effective amount varies according to factors such as the potency of the particular biotherapeutic medicament, the route of administration of the formulation, and the mechanical system used to administer the formulation.
  • a therapeutically effective amount of a particular drug can be selected by those of ordinary skill in the art with due consideration of such factors.
  • a therapeutically effective amount of biotherapeutic medicament will be from about 0.00001 parts by weight to about 5 parts by weight based on 100 parts by weight of the fluid or propellant selected.
  • a suitable fluid is one that carries and transports the construct particles having a selected medicament associated therewith and includes air, a hydrocarbon such as n-butane, propane, isopentane, etc. or a propellant.
  • a suitable propellant is any fluorocarbon, e.g.
  • a 1-6 hydrogen containing flurocarbon such as CHF 2 CHF 2 , CF 3 CH 2 F, CH2F2CH3 and CF 3 CHFCF 3
  • a perfluorocarbon e.g. a 1-4 carbon perfluorocarbon, (such as CF 3 CF 3 , CF 3 CF 2 CF 3 ); or any mixture of the foregoing, having a sufficient vapor pressure to render them effective as propellants.
  • Some typical suitable propellants include conventional chlorofluorocarbon (CFC) propellants such as propellants 11, 12 and 114 or a mixture thereof.
  • Non-CFC propellants such as 1,1,1,2-tetrafluoroethane (Propellant 134a), 1,1,1,2,3,3,3- heptafluoropropane (Propellant 227) or a mixture thereof are preferred.
  • the fluid or propellant is preferably present in an amount sufficient to propel a plurality of selected doses of drug in the form of construct particles from an aerosol canister when such is employed.
  • a suitable stabilizer includes (1) an amino acid selected from (a) a monoamino carboxylic acid of the formula, H N-R-COOH (I), (b) a monoamino dicarboxyhc acid of the formula, H 2 N- R(COOH) 2 (II) and (c) a diamino monocarboxylic acid of the formula (H 2 N) 2 -R COOH (IE), where R is a straight or branched alkyl radical of from 1 to 22 carbon atoms, which can be mono or poly-substituted with moieties such as sulfide (-S-), oxide (-O-), hydroxyl (-OH), amide (-NH), sulfate (-SO4); aryl of the formula
  • X is hydrogen, halogen (F, Cl, BR, I), alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, hydroxy and nitro; and heterocyclic, such as thienyl, furyl, pyranyl, imidazolyl, pyrrolyl, thizolyl, oxazolyl, pyridyl, and pyrimidinyl compounds;
  • a derivative of the amino acid selected from (a) acid addition salts of the amino group, obtained from inorganic acids, such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, and perchloric acids, as well as organic acids, such as tartaric, citric, acetic, succinic, maleic, fumaric, oxalic acids; (b) amides of the carboxylic acid group, e.g., glutamine, di-peptides, e.g.
  • esters of the carboxylic acid group obtained from aliphatic straight or branched chain alcohols of from 1 to 6 carbon atoms, e.g. L-aspartyl-L-phenylalanine methylester (Aspartame®), (3) an ether of any of the foregoing; (4) a hydrate or semi-hydrate of any of the foregoing and (5) a mixture of the amino acid and the derivative of the amino acid.
  • Suitable amino acids of the inventive formula include glycine, alanine, valine, leucine, isoleucine, leucylalanine, methionine, threonine, isovaline, phenylalanine, tyrosine, serine, cysteine, N-acetyl-L-cysteine, histidine, tryptophan, proline, and hydroxyproline, e.g. trans-4-hydroxy proline.
  • Compounds of the formula II include aspartic acid, and glutamic acid
  • compounds of the formula (III) include arginine, glutamine, lysine, hydroxylysine, ornithine, asparagine, and citrulline.
  • a fluid or aerosol formulation preferably comprises the protective colloid stabilizer in an amount effective to stabilize the formulation relative to an identical formulation not containing the stabilizer, such that the drug does not settle, cream or flocculate after agitation so quickly as to prevent reproducible dosing of the drug.
  • Reproducible dosing can be achieved if the formulation retains a substantially uniform drug concentration for about fifteen seconds to about five minutes after agitation.
  • the stabilizer is present either as a coarse carrier (e.g., 20-90 ⁇ m) or as a finely micronized powder, ⁇ 10 ⁇ m in diameter. In either case, reproducible drug dosimetry is obtained without the need to qualify the inspiratory maneuver of the patient. Accordingly, excellent dose uniformity is obtained at tidal flows of up to 2 liters, or at inspiratory flow rates of as low as 15 liters per minute to about 90 liters per minute.
  • a second suitable stabilizer is selected instead of the first stabilizer.
  • a second suitable stabilizer is a "water addition".
  • a "water addition” is an amount of water which (1) is added, either initially with other components of the described aerosol formulation, e.g. medicament associated with the polymeric construct as part thereof or encapsulated therein, and fluid carrier, or after the other components, e.g. medicament, fluid carrier, are combined and processed, (2) is in addition to the water which is always present and which develops during processing and/or storage of the aerosol formulation, i.e. "developed” or “nascent” formulation water, and (3) is present in an amount which further stabilizes a medicinal aerosol formulation, e.g.
  • An aerosol formulation preferably comprises the water addition in an amount effective to more effectively stabilize the formulation relative to an identical formulation not containing the water addition, i.e. containing only nascent formulation water, such that the drug e.g., an insulin containing construct, does not settle, cream or flocculate after agitation so quickly as to prevent reproducible dosing of the drug.
  • Reproducible dosing can be achieved if the formulation retains a substantially uniform drug concentration for about fifteen seconds to about five minutes after agitation.
  • the particular amount of stabilizer that constitutes an effective amount is dependent upon the particular stabilizer, the particular propellant, and on the particular drug used in the formulation. It is therefore not practical to enumerate specific effective amounts for use with specific formulations of the invention, but such amounts can readily be determined by those skilled in the art with due consideration of the factors set forth above.
  • the stabilizer can be present in a formulation in an amount from about 0.001 parts per million to about 200,000 parts per million, more preferably about 1 part per million to about 10,000 parts per million, most preferably from about 10 parts per million to about 5,000 parts per million of the total formulation.
  • the formulation of the invention is stable without the necessity of employing a cosolvent, such as ethanol, or surfactants.
  • a cosolvent such as ethanol, or surfactants.
  • further components such as conventional lubricants or surfactants, co-solvents, ethanol, etc., can also be present in an aerosol formulation of the invention in suitable amounts readily determined by those skilled in the art.
  • U.S. Patent No. 5,225,183 which is incorporated by reference hereinto in its entirety.
  • the formulations of the invention can be prepared by combining, matrixing, or encapsulating (i) the biotherapeutic medicament or drug with a sufficient amount of the modulating polymer in an amount sufficient to provide a plurality of therapeutically effective doses of the biotherapeutic; (ii) if necessary, adding an appropriate suspension stabilizer in an amount effective to stabilize each of the formulations; (iii) dispersing the matrixed or encapsulated and stabilized biotherapeutic medicament in an appropriate fluid or propellant in an amount sufficient to propel a plurality of doses, e.g. from an aerosol canister; and (iv) adding any further optional components, e.g. ethanol as a cosolvent; and homogenizing the components until a uniform dispersion is achieved.
  • the biotherapeutic medicament or drug with a sufficient amount of the modulating polymer in an amount sufficient to provide a plurality of therapeutically effective doses of the biotherapeutic
  • an appropriate suspension stabilizer in an amount effective to stabilize each of the formulations
  • the components can be dispersed using a conventional mixer or homogenizer, by shaking, or by ultrasonic energy.
  • the components can also be dispersed using a bead mill or a microfluidizer.
  • Bulk formulations can be transferred to smaller individual aerosol vials by using valve to valve transfer methods, pressure filling or by using conventional cold-fill methods. It is not required that a stabilizer used in a suspension aerosol formulation be soluble in the propellant. Those that are not sufficiently soluble can be coated onto the drug particles in an appropriate amount and the coated particles can then be incorporated in a formulation as described above.
  • Particles of the selected ABA block polymer system may be prepared using solutions or emulsion preparations of the polymer and active pharmaceutical ingredient which may subsequently be dried either by the use of an antisolvent such as carbon dioxide, nitrogen, or any other appropriate antisolvent, or by solvent evaporation, spray drying, solvent extraction, phase separation, coacervation, interfacial polymerization, and other methods well known to those of ordinary skill in the art.
  • Polymeric particles may be made also using microencapsulation, by nanoparticle technology, by coating methods such as spray congealing, by supercritical fluid technology, or by micellar solubilization where various techniques known to those skilled in the art may be used. These methods are described in the following non-exhaustive list of references which are incorporated hereinto by reference: (1) Doubrow, M., Ed., “Microcapsules and Nanoparticles in Medicine and Pharmacy," CRC Press, Boca Raton, 1992'
  • Hallworth et al United States Patent Number 4,206,758; (8) Hallworth et al, United States Patent Number 4,353,365;
  • Aerosol canisters equipped with conventional valves, preferably metered dose valves, can be used to deliver the formulations of the invention. It has been found, however, that selection of appropriate valve assemblies for use with aerosol formulations is dependent upon the particular stabilizer and other adjuvants used (if any), on the propellant, and on the particular drug being used. Conventional neoprene and buna valve rubbers used in metered dose valves for delivering conventional CFC formulations often have less than optimal valve delivery characteristics and ease of operation when used with formulations containing HFC- 134a or HFC-227.
  • certain formulations of the invention are preferably dispensed via a valve assembly wherein the diaphragm is made of a nitrile rubber such as DB-218 (American Gasket and Rubber, Schiller Park, 111.) or an EPDM rubber such as VistalonTM (Exxon), RoyaleneTM (UniRoyal), bunaEP (Bayer). Also suitable are diaphragms fashioned by extrusion, injection molding or compression molding from a thermoplastic elastomeric material such as FLEXOMERTM GERS 1085 NT polyolefin (Union Carbide).
  • DB-218 American Gasket and Rubber, Schiller Park, 111.
  • EPDM rubber such as VistalonTM (Exxon), RoyaleneTM (UniRoyal), bunaEP (Bayer).
  • diaphragms fashioned by extrusion, injection molding or compression molding from a thermoplastic elastomeric material such as FLEXOMERTM GERS 1085 NT polyolefin (
  • Conventional aerosol canisters coated or uncoated, anodized or unanodized, e.g., those of aluminum, glass, stainless steel, polyethylene terephthalate, and coated canisters or cans with epon, epoxy, etc., can be used to contain a formulation of the invention.
  • the formulation of the invention can be delivered to the respiratory tract and/or lung of the patient to be treated, e.g. a human being or other animal, by oral inhalation in order to effect bronchodilation or in order to treat a condition susceptible of treatment by inhalation, e.g., asthma, chronic obstructive pulmonary disease.
  • the formulation of the invention can also be delivered to the lung in order for the biotherapeutic agent to be delivered at measured rates to the systemic circulation for treatment of diseases elsewhere in the body, e.g., diabetes, hormone replacement, cancer, erythropoiesis, infection, or for immune protection such as achievable with vaccines.
  • the formulations of the invention can also be delivered by nasal inhalation in order to treat, for example, allergic rhinitis, rhinitis, (local) or diabetes (systemic), or they can be delivered via topical (e.g., buccal) administration in order to treat, e.g., angina or local infection.
  • nasal inhalation in order to treat, for example, allergic rhinitis, rhinitis, (local) or diabetes (systemic)
  • topical (e.g., buccal) administration in order to treat, e.g., angina or local infection.
  • the following formulations were prepared and placed in an aerosol container using Tetrafluoethane, HFA-134a propellant and ⁇ -cell hypoglycemics insulin and amylin as biotherapeutics. The delivery of the resultant formulation from the valve of the container was then measured.
  • the components of the formulations tabulated hereafter were using Pamasol pressure filling equipment, 20 ml aluminum cans (Cebal, coated with epoxy-phenolic inner-liner), and 50 microliter valves (Valois, DF10-RCU, nitrile rubber with polybutylterephthalate components).
  • Example 2 Insulin Matrixes in poly[D,L-lactic-co-glycolic acid] (PLGA)
  • Example 3 Insulin Matrixes in poly[D,L-lactic-co-glycolic acid] (PLGA)
  • Example 6 Amylin Matrixes in poly[D,L-lactic-co-glycolic acid] (PLGA) compositions with 0.005% PEG 400 as cross-linking agent
  • Example 7 Amylin Matrixes in poly[(p-carboxyphenoxy)-hexane anhydride] (PCPH) with PEG 400 as corss-linking agent
  • a Mass median aerodynamic diameter of prototype formulation
  • b Geometric standard deviation of the mean particle size data Stability conditions include room temperature storage and approximately 60% relative humidity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une préparation en aérosol à libération modulée, qui comprend un copolymère séquencé d'ABA biodégradable auquel est associé un médicament choisi. L'invention concerne en outre un support fluide servant à transporter et à administrer la préparation.
PCT/US2001/041129 2000-07-18 2001-06-25 Aerosols therapeutiques a liberation modulee WO2002005785A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001281288A AU2001281288A1 (en) 2000-07-18 2001-06-25 Modulated release therapeutic aerosols

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21905400P 2000-07-18 2000-07-18
US60/219,054 2000-07-18
US70231900A 2000-10-31 2000-10-31
US09/702,319 2000-10-31

Publications (1)

Publication Number Publication Date
WO2002005785A1 true WO2002005785A1 (fr) 2002-01-24

Family

ID=26913518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041129 WO2002005785A1 (fr) 2000-07-18 2001-06-25 Aerosols therapeutiques a liberation modulee

Country Status (2)

Country Link
AU (1) AU2001281288A1 (fr)
WO (1) WO2002005785A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078211A1 (fr) * 2003-03-04 2004-09-16 Tanabe Seiyaku Co., Ltd. Preparation en poudre pour l'administration nasale
WO2006002840A2 (fr) * 2004-07-02 2006-01-12 Boehringer Ingelheim International Gmbh Formulations de suspensions aerosol contenant tg 227 ea ou tg 134 a en tant qu'agent propulseur
WO2008053250A3 (fr) * 2006-10-31 2008-07-24 Univ London Pharmacy Formulations administrées par inhalateurs doseurs pressurisés
WO2009150120A1 (fr) * 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh Nouvelles émulsions pour la préparation de médicaments
WO2009150136A1 (fr) * 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh Nouvelles particules à principe actif incorporé pour inhalation
US8518377B2 (en) 2006-04-11 2013-08-27 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
EP3252068A2 (fr) 2009-10-12 2017-12-06 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
CN107810220A (zh) * 2015-07-09 2018-03-16 赢创罗姆有限公司 制备聚(乙交酯‑共聚‑丙交酯)共聚物微粒的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6004573A (en) * 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOKSER ET AL.: "Delayed release formulation of the somatostatin analog RC-160 inhibits the growth hormone (GH) response to GH-releasing factor -(1-29)NH2 and decreases elevated prolactin levels in rats", ENDOCRINOLOGY, vol. 123, no. 4, 1988, pages 1735, XP002948433 *
FUERNSINN ET AL.: "Troglitazone directly inhibits CO2 production from glucose and palmitate in isolated rat skeletal muscle", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 293, no. 2, 2000, pages 487, XP002948434 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004078211A1 (ja) * 2003-03-04 2006-06-08 田辺製薬株式会社 粉末経鼻投与製剤
US7591999B2 (en) 2003-03-04 2009-09-22 Mitsubishi Tanabe Pharma Corporation Powdery preparation for nasal administration
WO2004078211A1 (fr) * 2003-03-04 2004-09-16 Tanabe Seiyaku Co., Ltd. Preparation en poudre pour l'administration nasale
JP4493594B2 (ja) * 2003-03-04 2010-06-30 田辺三菱製薬株式会社 粉末経鼻投与製剤
AU2005259523B2 (en) * 2004-07-02 2011-06-09 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as a propellant
WO2006002840A2 (fr) * 2004-07-02 2006-01-12 Boehringer Ingelheim International Gmbh Formulations de suspensions aerosol contenant tg 227 ea ou tg 134 a en tant qu'agent propulseur
WO2006002840A3 (fr) * 2004-07-02 2006-11-16 Boehringer Ingelheim Int Formulations de suspensions aerosol contenant tg 227 ea ou tg 134 a en tant qu'agent propulseur
JP2008504325A (ja) * 2004-07-02 2008-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 噴霧剤としてｔｇ２２７ｅａ又はｔｇ１３４ａを含有するエアロゾル懸濁製剤
EP1809243B2 (fr) † 2004-07-02 2022-06-08 Boehringer Ingelheim International GmbH Formulations de suspensions aerosol contenant tg 227 ea en tant qu'agent propulseur
US8357352B2 (en) 2004-07-02 2013-01-22 Boehringer Ingelheim International Gmbh Aerosol suspension formulations containing TG 227 ea or TG 134 a as propellant
EA013428B1 (ru) * 2004-07-02 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх РАСПЫЛЯЕМЫЕ В ВИДЕ АЭРОЗОЛЯ СУСПЕНЗИОННЫЕ КОМПОЗИЦИИ С TG 227ea ИЛИ TG 134a В КАЧЕСТВЕ ПРОПЕЛЛЕНТА
US8518377B2 (en) 2006-04-11 2013-08-27 Boehringer Ingelheim Pharma Gbmh Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
EP2364696A1 (fr) * 2006-10-31 2011-09-14 School Of Pharmacy, University Of London Formulations pour administration par inhalateur-doseur pressurisé
WO2008053250A3 (fr) * 2006-10-31 2008-07-24 Univ London Pharmacy Formulations administrées par inhalateurs doseurs pressurisés
JP2011522859A (ja) * 2008-06-09 2011-08-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入用の新規な埋込み粒子
WO2009150136A1 (fr) * 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh Nouvelles particules à principe actif incorporé pour inhalation
WO2009150120A1 (fr) * 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh Nouvelles émulsions pour la préparation de médicaments
EP3252068A2 (fr) 2009-10-12 2017-12-06 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
EP4089169A1 (fr) 2009-10-12 2022-11-16 Larry J. Smith Procédés et compositions permettant de moduler l'expression génique à l'aide de médicaments à base d'oligonucléotides administrés in vivo ou in vitro
CN107810220A (zh) * 2015-07-09 2018-03-16 赢创罗姆有限公司 制备聚(乙交酯‑共聚‑丙交酯)共聚物微粒的方法

Also Published As

Publication number Publication date
AU2001281288A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
CA2438218C (fr) Particules a liberation modulee d'administration d'un aerosol
US6551578B2 (en) Modulated release particles for aerosol delivery
US6475468B2 (en) Modulated release particles for aerosol delivery
US6585957B1 (en) Medicinal aerosol formulation
AU2002255541A1 (en) Modulated release particles for aerosol delivery
AU2002243947A1 (en) Modulated release particles for aerosol delivery
AU2002245410A1 (en) Modulated release particles for aerosol delivery
WO2001054664A1 (fr) Procede d'administration d'une formulation aerosol medicale
US6669959B1 (en) Modulated release particles for lung delivery
US6485707B2 (en) Modulated release particles for aerosol delivery
AU2002306462A1 (en) Modulated release particles for aerosol delivery
WO2001082873A2 (fr) Formulation medicamenteuse pour aerosol
AU2001226234A1 (en) A medicinal aerosol formulation
WO2002005785A1 (fr) Aerosols therapeutiques a liberation modulee
AU2001224727A1 (en) A method of treating a systemic disease
EP1313450A1 (fr) Procede pour le traitement d'une maladie systemique
US20030035774A1 (en) Salt/ion pair medicinal aerosol formulation
CA2396796C (fr) Preparations medicinales stabilisees contenant des particules d'aerosol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载